On November 5, 2018 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, reported that Co-Founder and Chief Executive Officer (CEO) Matthew R. Patterson has been appointed Chairman of the Board of Directors (Press release, Audentes Therapeutics, NOV 5, 2018, View Source [SID1234530738]). The Board of Directors also appointed Louis G. Lange, M.D., Ph.D. as Lead Independent Director. Mr. Patterson and Dr. Lange have held board member roles since 2012 and 2015, respectively.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"It is a great privilege for me to serve our company as Chairman of the Board of Directors," stated Matthew R. Patterson, Chairman and CEO. "Audentes is at an exciting inflection point, and I look forward to working closely with the board and management team to deliver on important milestones that advance our mission of developing innovative gene therapy products for patients living with serious, life-threatening rare diseases."
Mr. Patterson continued, "I am also pleased to announce the appointment of Dr. Lange to the position of Lead Independent Director. Lou is a recognized leader in the biotechnology industry who brings a unique and valued perspective to our organization. We’re fortunate to benefit from Lou’s deep experience gained over a successful career as a physician and founder and CEO of innovative public biotechnology companies, and I look forward to partnering with him in the leadership of our board."
Mr. Patterson has more than 25 years of experience in the research, development, and commercialization of innovative treatments for rare diseases and has held positions of senior management in both private and public biotechnology companies. Previously Mr. Patterson worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed, one of the world’s largest healthcare dedicated investment firms. Mr. Patterson currently serves as Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He is a member of the Board of Directors for Homology Medicines, Inc., Modis Therapeutics, Inc., and Gilda’s Club of New York City, which provides support for people living with cancer. Mr. Patterson received his Bachelor’s degree in Biochemistry from Bowdoin College.
Dr. Lange was the founder of CV Therapeutics, and as the Chairman, CEO, and Chief Scientific Officer, led the company through an IPO, the approval of two first-in-class cardiovascular drugs, RANEXA and LEXISCAN, and the sale of the company to Gilead Sciences, Inc. Prior to joining industry, Dr. Lange spent 22 years in academic medicine at Harvard and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital and was one of the first academicians in molecular cardiology. Dr. Lange is currently a General Partner at Asset Management Ventures, serves as a senior advisor to Gilead Sciences, Inc., and has served on numerous other public and private boards in both the non-profit and for-profit sectors. Dr. Lange holds a Doctorate degree in Biochemistry from Harvard University and a Medical Doctor degree from Harvard Medical School. He earned a Bachelor’s degree from the University of Rochester.